“Lebrikizumab Improves Atopic Dermatitis and ​Quality of Life in Patients With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab: ​ Results From the ADapt Trial” (2025) SKIN The Journal of Cutaneous Medicine, 9(1), p. s512. doi:10.25251/skin.9.supp.512.